CJC-1295 vs Ipamorelin vs the Blend: Choosing a GH Stack

CJC-1295 is a GHRH analog; Ipamorelin is a GH secretagogue. The blend combines both pathways. Compare mechanisms, pulse profiles, and study signals.

CJC-1295 and ipamorelin are two lab-made peptides that both raise growth hormone (GH), but they do it through different doors. CJC-1295 copies the body’s GHRH hormone and tells the pituitary gland to make and release GH. Ipamorelin copies the hunger hormone ghrelin and tells the same gland to release stored GH. Because they push two different buttons, using them together gives a bigger GH burst than either one alone. This guide explains how each works, what the blend does, and which setup fits which research question.^[1][2][3]

See how this fits the wider landscape of growth-hormone and muscle research peptides.

This content is for education only and is not medical advice. The peptides discussed are for laboratory research only and are not approved for human use.

Peptides sold for lab research also sit inside a specific legal category in Canada and the U.S. — see our guide to the legal framework for buying peptides in Canada for the full picture.

How does the body control growth hormone?

The body controls GH with a push-and-pull system in the brain and pituitary gland. The pituitary releases GH, and two brain hormones mostly steer it: GHRH (which says “release GH”) and somatostatin (which says “stop”). A third path, run by the hormone ghrelin, adds more “release” power and is a key target for lab peptides.

The GHRH path and the ghrelin path

There are two main “go” signals for GH, and they work side by side:

The GHRH path: GHRH is made in the brain and travels to the pituitary, where it binds the GHRH receptor on GH-making cells. This both builds new GH and releases it.
The ghrelin path: Ghrelin, the “hunger hormone,” is made mostly in the stomach and also acts on the pituitary. It binds a different receptor called GHS-R1a. This also strongly releases GH, but through a different inside-the-cell route, and it also turns down somatostatin, the body’s main GH “brake.”

Because these two paths use different receptors, you can push both at once. Doing so does not just add the two effects together; it multiplies them, giving a much bigger GH release than the sum of the parts.^[3]

What is CJC-1295?

CJC-1295 is a lab-made copy of GHRH, built to last much longer than natural GHRH. It does the same job, telling the pituitary to make and release GH, but changes make it more stable. The big thing to know is that it comes in two forms, with and without a part called DAC (Drug Affinity Complex).

DAC vs. no DAC (MOD GRF 1-29)

The naming here trips people up. What is often called “CJC-1295 without DAC” is more correctly named MOD GRF 1-29. It is a changed version of the first 29 building blocks of GHRH, and it lasts only about 30 minutes. That short window makes it good for creating a sharp, controlled GH pulse.

True CJC-1295 with DAC adds the DAC part. This is a small linker that lets the peptide lock onto albumin, a common blood protein. That shields it from being broken down or cleared, stretching its half-life to about 8 days. In healthy adults, a single dose of CJC-1295 raised GH for several days and IGF-1 (a downstream growth signal) for about 9 to 11 days.^[1] So instead of a sharp pulse, the DAC form gives a steady, raised baseline of GH and IGF-1, often called a “GH bleed.”

What is ipamorelin?

Ipamorelin is a small, clean ghrelin-copy peptide that releases GH without raising stress hormones. It is a pentapeptide, meaning five building blocks. Its main draw in the lab is how selective and gentle it is in animal studies. Unlike older peptides, it releases GH with very little side action.

Clean, selective action

Ipamorelin works by switching on the GHS-R1a receptor, the same one ghrelin uses. What sets it apart from older peptides like GHRP-6 and GHRP-2 is its focus. Research shows those older peptides also raise cortisol (a stress hormone) and prolactin, while ipamorelin barely touches them.^[2] That makes it a great tool for studying a “clean” GH pulse without extra hormones muddying the results.

A natural-looking pulse

With a half-life of about 2 hours, ipamorelin makes a strong but short GH pulse. This looks a lot like the body’s own pattern, which comes in bursts, mostly during deep sleep. That pulse pattern is thought to matter for proper signaling and for avoiding receptor burnout. Key points about ipamorelin:

Highly selective for the GHS-R1a (ghrelin) receptor.
Makes a strong, clean GH pulse.
Animal data shows little to no effect on cortisol or prolactin.
Short half-life gives a natural-looking, pulse-style release.

Why combine them into a blend?

The blend works because it pushes both GH “go” buttons at the same time. By giving CJC-1295 (the short MOD GRF 1-29 form) and ipamorelin together, researchers fire the two separate GH paths at once, getting a response much bigger than either alone.

Think of it this way: MOD GRF 1-29 (the GHRH copy) hits the GHRH receptors to “prime the pump.” It builds up GH inside the pituitary cells and gets them ready. Right after, ipamorelin hits the GHS-R1a to give a strong, separate “release now” signal. It is like filling a tank to the top (MOD GRF 1-29), then opening the floodgates (ipamorelin).

On top of that, the ghrelin path ipamorelin uses also turns down somatostatin, the body’s main GH brake. So you get a strong “go” from both paths plus a release of the brake, which gives a big GH pulse, ideal for studying the most GH the pituitary can put out.^[3]

Which setup fits which research goal?

The right choice depends fully on the research question. Each setup makes a different hormone pattern with different downstream effects.

Comparing the hormone patterns

CJC-1295 with DAC (alone): No strong pulses. Instead, a steady, low rise in GH that leads to a stable, higher IGF-1. Good for studying the long-term effects of raised IGF-1 without big GH pulses.
Ipamorelin (alone): Sharp, clean, natural-looking GH pulses that drop back fast. Best for studying the quick effects of GH or why the pulse pattern matters.
The blend (MOD GRF 1-29 + ipamorelin): The most common research stack. It uses the two-path synergy to make a maximum, high-peak GH pulse. Good for dose-response work and testing the upper limit of pituitary output.

In short, stacking matters because it lets researchers fine-tune the GH system. A long-acting GHRH copy gives a steady “bleed,” while a short GHRH copy plus a ghrelin peptide gives a powerful “burst.” That difference is key, since many of GH’s effects depend on its pulse-style delivery.

Why purity testing matters more for this stack

Purity testing matters more here because CJC-1295 and ipamorelin sit on two completely different points on the mass scale and work through two separate receptors, so a lab test can tell you exactly which peptide, or how much of each, is really in the vial. A Certificate of Analysis (COA) usually reports two numbers: HPLC purity (how much of the vial is the target peptide, versus leftover junk from synthesis) and a mass spectrometry (MS) reading, a test that weighs the molecule and checks it against the expected mass.^[4] For a GHRH-copy-plus-ghrelin-copy stack, that mass reading matters more than usual, because the two peptides don’t just have different jobs, they have different weights:

CJC-1295 with DAC: formula C165H269N47O46, about 3,647 g/mol.^[5] The extra weight compared with MOD GRF 1-29 comes from the DAC linker that grabs onto albumin.
MOD GRF 1-29 (CJC-1295 without DAC): formula C152H252N44O42, about 3,368 g/mol.^[5] That’s roughly 280 g/mol lighter than the DAC version, and the two get mixed up in listings constantly because they share a name.
Ipamorelin: formula C38H49N9O5, about 712 g/mol.^[5] It’s a much smaller molecule, because it acts on GHS-R1a, a completely different receptor than the GHRH copies use.

This gap matters for a practical reason: because CJC-1295 (in either form) and ipamorelin work on separate receptors, a vial missing one of the two peptides doesn’t just make a “weaker” version of the blend, it fails to trigger one whole pathway. A blend vial with a strong CJC-1295 mass peak but no ipamorelin peak will only “prime the pump,” it won’t “open the floodgates,” so the two-path synergy described above never happens. A generic HPLC purity number like “98% pure” doesn’t catch this, since that figure can describe a single, correctly-made peptide that has no second peptide in the vial at all. Before using a CJC-1295, MOD GRF 1-29, or blend vial for research, ask the supplier for a COA that reports a separate mass spec reading for each peptide component, and check the reported mass against the numbers above.

CJC-1295 and ipamorelin questions

What is the difference between CJC-1295 with and without DAC?

The big difference is how long it lasts and what it does to GH. Without DAC (really MOD GRF 1-29), the half-life is about 30 minutes and it makes a short, sharp GH pulse. With DAC, the half-life is about 8 days because it locks onto the blood protein albumin. That gives a steady, raised baseline of GH and IGF-1, a “GH bleed,” instead of a clear pulse.

Why is ipamorelin called more “selective”?

Selective means it acts on the GHS-R1a receptor without stirring up other hormones. Older GH-releasing peptides like GHRP-6 and GHRP-2 also release GH, but they raise cortisol and prolactin too. Research shows ipamorelin’s design lets it make a strong GH pulse with little or no effect on those other hormones, so it is a “cleaner” tool.

Is a blend always better than a single peptide?

No, the best setup depends on the question. A blend like MOD GRF 1-29 plus ipamorelin is best for a maximum, combined GH pulse. But to study long-term raised IGF-1 with few GH pulses, CJC-1295 with DAC alone fits better. To copy a natural GH pulse with no extra hormones, ipamorelin alone is ideal. Each one serves a different purpose.